
The Mediterranean League Against Thromboembolic Diseases

Spanish Society of Thrombosis and Haemostasis

Abstracts

13th International Congress
on Thrombosis

10th National S.E.T.H. Congress

6th Nursing Workshop

June 6-10, 1994
Bilbao (Spain)

Guest Editors

J. A Iriarte (Bilbao)

J. Monasterio (Barcelona)

J. M. de Gandarias (Bilbao)

J. P. Sáez de Lafuente (Bilbao)

ORGANIZING COMMITTEE

President: J. A. Iriarte

Vicepresidents: J. Aznar

J. Battle

J. M. de Gandarias

Scientific Secretariat:

Y. Sáez

J. P. Sáez de Lafuente

Members: R. Carmona

J. L. Chacón

M. T. Del Hierro

† M. J. Domínguez

C. Fernández

P. Lafuente

J. Lasiera

A. Magro

J. Múgica

I. Narváez

J. L. Navarro

A. Ordinas

A. Pascual

C. Pérez-Clausell

J. A. Pérez Gómez

E. Rocha

M. Ll. Rutllant

E. Sabino

I. Santos

I. Urkidi

A. Velasco

C. Villaverde

COUNTRY COUNCILLORS OF THE MEDITERRANEAN LEAGUE AGAINST THROMBOEMBOLIC DISEASES

J. Aznar (Spain)

R. Baklaja (Yugoslavia)

S. Coccheri (Italy)

R. Houissia (Tunisia)

J. A. Iriarte (Spain)

D. Keber (Slovenia)

T. Mandalaki (Greece)

A. G. Mustafa (Egypt)

M. M. Samama (France)

U. Seligsohn (Israel)

N. Taleb (Lebanon)

J. B. Topalov (Bulgaria)

O. N. Ulutin (Turkey)

SPANISH SOCIETY OF THROMBOSIS AND HAEMOSTASIS

President: J. Battle

Vicepresidents: A. Fernández Pavón

F. Sánchez de la Cuesta

J. Monasterio

Secretary: E. Reganón

Book-keeper: M. A. Fernández

Treasurer: F. España

Librarian: J. P. de la Cruz

Members: L. J. García-Frade

J. Gilabert

J. A. Iriarte

J. Lasiera

M. F. López-Fernández

F. Martínez-Brotóns

M. Monreal

J. A. Páramo

M. T. Santos

J. Vallés

V. Vicente

Haemostasis

Vol. 24, Supplement I, 1994

SCIENTIFIC PROGRAM COMMITTEE

President: J. Monasterio

L. Badimón (Spain)	A. López Borrasca (Spain)
P. Balas (Greece)	A. Lucic (Yugoslavia)
J. L. Bóveda (Spain)	P. M. Mannucci (Italy)
M. Boisseau (France)	P. Martínez-Brotos (Spain)
G. V. R. Born (UK)	M. Monreal (Spain)
H. K. Breddin (Germany)	G. G. Neri Serneri (Italy)
M. Brochier (France)	J. A. Páramo (Spain)
R. Castillo (Spain)	M. Picó (Spain)
A. Charrad (Tunisia)	L. Poller (UK)
A. Eldor (Israel)	C. R. M. Prentice (UK)
S. I. Elwan (Egypt)	E. Reganón (Spain)
J. Félez (Spain)	F. Sánchez de la Cuesta (Spain)
A. Fernández Pavón (Spain)	A. Strano (Italy)
G. de Gaetano (Italy)	J. Vallés (Spain)
L. J. García Frade (Spain)	V. Vicente (Spain)
H. C. Hermker (The Netherlands)	M. Vilardel (Spain)
J. A. Jiménez Cossío (Spain)	H. Vinazzer (Austria)
S. Levy-Toledano (France)	T. Yardimci (Turkey)

S. Karger
Medical and Scientific Publishers
Basel · München · Paris · London
New York · New Delhi · Bangkok
Singapore · Tokyo · Sydney

Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see "Information for Readers and Subscribers").
© Copyright 1994 by S. Karger AG,
P.O. Box, CH-4009 Basel (Switzerland)
Printed in Spain on acid-free paper by
Gramagraf, Barcelona D.L. B-21.576-94
ISBN 3-8055-6020-6

Acknowledgments

We are grateful for the generosity of support
pledged to the publishing of the
Abstracts Book
by
Hoechst Ibérica, S.A. (Barcelona) Spain

CONTENTS

Numbers refer to Abstract No.

	Abstract No.
I. 13th INTERNATIONAL CONGRESS ON THROMBOSIS	
PLENARY LECTURES	
● Thrombolysis for Acute Myocardial Infarction. Van de Werf F.	1
● Thrombin in Arterial Thrombosis. Badimon L, Meyer B J, Badimon J J.	2
● Molecular Genetics Aspects of Factor XI Deficiency and Glanzmann Thrombasthenia Seligsohn U, Peretz H.	3
● Venous Thrombosis Today Kakkar V V.	4
● Mechanisms for the Antithrombotic Activity, in Man, of Low Molecular Weight Heparins (LMWHs). Samama M M, Bara L, Gerotziafas G T.	5
● Antithrombotic Drugs in Peripheral Obliterative Arterial Disease (POAD) Coccheri S, Palareti G, Fortunato G.	6
● Cancer and Thrombosis. Donati M B.	7
● Inflammatory Mediators and their Influence on Haemostasis. Salgado A, Bóveda J L, Monasterio J, Segura R M, Mourelle M, Gómez-Jiménez J, Peracaula R.	8
● Inherited Resistance to Activated Protein C, a Major Cause of Venous Thrombosis, is due to Deficient Anticoagulant Cofactor Function of Factor V. Dahlbäck B.	9

SYMPOSIA

- Thrombolysis for AMI and Venous Thromboembolism. 10 - 14
Chairpersons: **Neri Sernerì GG., Lasierra J.**
- Non Invasive Diagnostic Methods for Arterial and Venous Thrombosis. 15 - 19
Chairpersons: **Breddin H K, Pérez Gómez F, Velasco A.**
- Prophylaxis of Venous Thrombosis and Pulmonary Embolism in Hip Surgery 20 - 24
Chairpersons: **Bergquist D, Monreal M.**
- Epidemiology of Venous and Arterial Thrombosis in the General Population. 25 - 31
Chairpersons: **Girolami A, Iriarte J A.**
- Primary Prevention of Venous Thromboembolic Disease in Medical Patients. 32 - 36
Chairpersons: **Samama M M, Rocha E.**
- Age-related Risk Factors in Atherosclerosis and Thrombosis. 37 - 42
Chairpersons: **Ulutin O N, Carmena R.**
- The Clinical Experience of LMWH in the Treatment of Deep Venous Thrombosis. 43 - 47
Chairpersons: **Kakkar V V, Monasterio J.**
- Antithrombotic Therapy in Peripheral Vascular Diseases. 48 - 50
Chairpersons: **Cocchery S, Strano A.**
- Lupus Anticoagulants and Antiphospholipid Antibodies: New Trends. 51 - 57
Chairpersons: **Tripplè D A, Ordi J.**
- Haemorrhéology, Hiperlipidemia and Diabetes. 58 - 63
Chairpersons: **Boisseau M R, Vaya A.**
- Tissular Factor and Thrombosis. 64 - 67
Chairpersons: **Broze G J, Félez J.**
- Recent Advances in Perinatal Haemostasis. 68 - 71
Chairpersons: **Gilabert J, Estellés A.**
- Cellular Interactions and Thrombo-regulation. 72 - 75
Chairpersons: **Marcus A J, Aznar J.**
- Membrane Signal Transmission. Basic Aspects and Therapeutic Implications. 76 - 79
Chairpersons: **Levy Toledano S, de Gaetano G.**
- Genetic Engineering for Diagnosis and Treatment in Haemostasia. 80 - 83
Chairpersons: **Manucci P M, Navarro J. L.**
- Controversies Today Resolved and Proposals for the Future, Regarding the Antithrombotic Drugs in Use and those of New Generation. 84 - 87
Chairpersons: **Poller L, Iriarte J A.**

- Venous Thromboembolic Disease. Biological Tests and Diagnosis. 88 - 93
Chairpersons: **Boneu B, Rutllant M LL.**
- Biological Risk Markers for Arterial Thrombosis. 94 - 98
Chairpersons: **Mandalaki T, Prentice C R M.**

ORAL COMMUNICATIONS AND POSTERS

- Epidemiology. Age Related Aspects of Thrombosis and Atherosclerosis. Lipids and Atherothrombosis.
 - Oral Communications 99- 115
 - Posters 116 - 134
- Biological Aspects of Venous Thrombosis Disease.
 - Oral Communications 135 - 144
 - Posters 145- 161
- Fibrinolysis and Thrombolysis.
 - Oral Communications 162 - 174
 - Posters 175 - 180
- Cellular Participation in Inflammation, Atherosclerosis and Thrombosis.
 - Oral Communications 181 - 189
 - Posters 190 - 196
- Biological Markers, Predictive of Thrombosis
 - Oral Communications 197 - 208
 - Posters 209 - 228
- Controversial Aspects of Prophylaxis, Diagnostics And Treatment of Thrombosis, for which Consensus is aimed in 1994.
 - Oral Communications 229 - 239
- Antithrombotic Treatment and its Control:
 1. **Updating of Antithrombotic Drugs in Use and those of New Generation.**
 - Oral Communications 240 - 257
 2. **Biological Control of Antithrombotic Drugs.**
 - Oral Communications 258 - 264
 3. **Thrombolytics and their Current Indications.**
 - Oral Communications 265 - 266
 4. **Updating of the Antithrombotic Drugs in use and those of New Generation.**
 - Posters 267 - 289
 5. **Biological Control of Antithrombotic Drugs.**
 - Posters 290 - 294

6. Standardisation, Quality Control and Automatization	
– Posters	300-309
● Haemostasis Alterations in Different Pathologies:	
1. Malignancy, Haemostasis and Thrombosis.	
– Oral Communications	300 - 309
– Posters	310 - 321
2. Obstetrics, Neonatology and Coagulopathies.	
– Posters	322 - 323
3. Congenital Thrombopathies and Coagulopathies.	
– Posters	324 - 330
4. Immunocoagulation, AIDS.	
– Posters	331 - 337
● Advances in Haemorrhology and Microcirculation and Post-infarct Miocardic Rethrombosis.	
– Oral Communications	338 - 345
– Posters	346 - 357
● Special Topics.	
– Oral Communications	358 - 364
– Posters	365 - 369
II. 6th NURSING WORKSHOP PROGRAM. SYMPOSIA.	
● Epidemiology.	370 - 375
Chairperson: Del Hierro M T.	
● Nursing and Venous Thrombotic Disease in Orthopaedic Surgery. I.	376 - 381
Chairperson: Fernández A.	
● Nursing and Venous Thrombotic Disease in Orthopaedic Surgery. II.	382 - 386
Chairperson: Alba Gallardo I.	
● Thrombosis and Haemostasis.	387 - 391
Chairperson: Aguirrebeitia M J.	
● Intensive care.	392 - 394
Chairperson: González Sanz I.	
	Page No.
Authors Index	395 - 402
Subject Index	403 - 410